NASDAQ:ONCS OncoSec Medical (ONCS) Stock Forecast, Price & News $0.44 -0.01 (-2.23%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$0.41▼$0.4650-Day Range$0.44▼$2.7352-Week Range$0.40▼$20.68Volume155,121 shsAverage Volume1.80 million shsMarket Capitalization$1.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About OncoSec Medical (NASDAQ:ONCS) StockOncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Ewing, NJ.Read More Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCS Stock News HeadlinesMay 26, 2023 | americanbankingnews.comOncoSec Medical (NASDAQ:ONCS) Downgraded by StockNews.comMay 18, 2023 | finance.yahoo.comOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 30, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 16, 2023 | msn.comOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockMay 16, 2023 | finance.yahoo.comOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programMay 13, 2023 | americanbankingnews.comOncoSec Medical (NASDAQ:ONCS) Upgraded to "Hold" by StockNews.comApril 27, 2023 | finance.yahoo.comOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ProgramMay 30, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 11, 2023 | finance.yahoo.comOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 10, 2023 | msn.comWhy OncoSec Medical Shares Are Soaring TodayApril 10, 2023 | finance.yahoo.comOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 6, 2023 | benzinga.comOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket TradingApril 3, 2023 | finance.yahoo.comOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting StudyApril 3, 2023 | msn.comOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialApril 3, 2023 | finance.yahoo.comOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentMarch 1, 2023 | marketwatch.comOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%March 1, 2023 | msn.comWhy is OncoSec Medical (ONCS) Stock Up 91% Today?January 16, 2023 | reuters.comONCS.OQ - | Stock Price & Latest News | ReutersJanuary 5, 2023 | benzinga.comOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News SummaryDecember 8, 2022 | msn.comPeering Into OncoSec Medical's Recent Short InterestDecember 5, 2022 | finance.yahoo.comOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022November 30, 2022 | marketwatch.comOncoSec Shares Drop 25% on Equity Offer Pricing After 51% Tuesday SurgeNovember 30, 2022 | finance.yahoo.comOncoSec Announces Pricing of $3.5 Million Public OfferingNovember 24, 2022 | finance.yahoo.comOncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin CancerNovember 23, 2022 | seekingalpha.comOncoSec provides updates on cancer programs in new filingNovember 22, 2022 | msn.comLooking Into OncoSec Medical's Recent Short InterestSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCS Company Calendar Last Earnings3/13/2023Today5/30/2023Next Earnings (Estimated)6/13/2023Fiscal Year End7/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS CUSIPN/A CIK1444307 Webwww.oncosec.com Phone(855) 662-6732Fax858-430-3832Employees54Year Founded2011Profitability EPS (Most Recent Fiscal Year)($15.2865) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-868.29% Return on Assets-160.61% Debt Debt-to-Equity RatioN/A Current Ratio0.89 Quick Ratio0.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.13Miscellaneous Outstanding Shares4,550,000Free Float4,494,000Market Cap$1.99 million OptionableNot Optionable Beta1.99 Social Links Key ExecutivesRobert H. ArchPresident, CEO & Non-Independent DirectorGeorge ChiChief Financial OfficerDavid CantonVice President-Research & DevelopmentSandra AungChief Clinical Development Officer & Senior VPBridget O'KeeffeVice President-Clinical DevelopmentKey CompetitorsCalithera BiosciencesNASDAQ:CALAAyala PharmaceuticalsNASDAQ:ADXSSciSparcNASDAQ:SPRCScopus BioPharmaNASDAQ:SCPSStatera BiopharmaNASDAQ:STABView All CompetitorsInsiders & InstitutionsFNY Investment Advisers LLCBought 105,690 shares on 4/12/2023Ownership: 3.559%Robert J DelaversanoSold 40 sharesTotal: $54.80 ($1.37/share)Robert J DelaversanoSold 283 sharesTotal: $104.71 ($0.37/share)Robert J DelaversanoSold 284 sharesTotal: $201.64 ($0.71/share)View All Insider TransactionsView All Institutional Transactions ONCS Stock - Frequently Asked Questions Should I buy or sell OncoSec Medical stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares. View ONCS analyst ratings or view top-rated stocks. How have ONCS shares performed in 2023? OncoSec Medical's stock was trading at $1.68 at the start of the year. Since then, ONCS shares have decreased by 73.9% and is now trading at $0.4380. View the best growth stocks for 2023 here. Are investors shorting OncoSec Medical? OncoSec Medical saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 49,100 shares, a decline of 63.6% from the April 30th total of 135,000 shares. Based on an average daily trading volume, of 2,710,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.3% of the shares of the company are short sold. View OncoSec Medical's Short Interest. When is OncoSec Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 13th 2023. View our ONCS earnings forecast. How were OncoSec Medical's earnings last quarter? OncoSec Medical Incorporated (NASDAQ:ONCS) posted its quarterly earnings results on Monday, March, 13th. The biotechnology company reported ($2.65) EPS for the quarter. When did OncoSec Medical's stock split? OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Punit Dhillon's approval rating as OncoSec Medical's CEO? 2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN). What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." Who are OncoSec Medical's major shareholders? OncoSec Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (3.56%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao. View institutional ownership trends. How do I buy shares of OncoSec Medical? Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $0.44. How much money does OncoSec Medical make? OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $1.99 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832. This page (NASDAQ:ONCS) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoSec Medical Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.